MIRM's logo.
Ticker Symbol: MIRM

Mirum Pharmaceuticals Inc

$15.89 - 20-11-2024 4 p.m. ET

Exchange: NASDAQ Currency: USD Asset Type: Common Stock CIK:0001759425

Company Profile

Mirum Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. Mirum's lead product candidate, maralixibat, is an investigational oral drug in development for Alagille syndrome (ALGS), progressive familial intrahepatic cholestasis (PFIC), and biliary atresia. Mirum has submitted an NDA for maralixibat in the treatment of cholestatic pruritus in patients with ALGS. Additionally, Mirum's marketing authorization application for the treatment of pediatric patients with PFIC2 has been accepted for review (validated) by the European Medicines Agency.

Sector: Professional, Scientific, and Technical Services
Industry: Research and Development in Biotechnology
Standard Industrial Classification Code (SIC code): 2834
Address: N/A
CEO: N/A
Tags:
  • Health Technology
  • Pharmaceuticals: Major

Pricing

Last Updated: October 3, 2023 03:00 PM EST
Previous Close: $29.77
Change: $0.47 ( 1.60%)
Days Range: $29.09 - $30.08
Beta: 0.86
52wk. High: $33.39
52wk. Low: $17.48
Ytd. Change 51.86%
50 Day Moving Average: $29.91
200 Day Moving Average: $27.22
Shares Outstanding: 38297975

Valuation

Market Cap: 114.0B
PE Ratio: -6.25
EPS (TTM): -4.76

Dividends

Dividend Per Share (TTM): -
Dividend Yield (TTM): 0.00%
Ex-Dividend Date: N/A